HURA
NASDAQTuHURA Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings4
News · 26 weeks34-57%
2026-04-262026-10-18
Mix1990d
- SEC Filings12(63%)
- Other7(37%)
Latest news
25 items- SECSEC Form 8-K filed by TuHURA Biosciences Inc.8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodiesTAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office (USPTO) has issued Patent No. 12,760,104 entitled, "Anti-VISTA Antibodies and Uses Thereof."The new patent claims provide coverage for TBS-2025, TuHURA's VISTA inhibiting antibody, as well as antigen-binding fragments, modifications to the frameworks and Fc regions of the antibody, and bi-specific/m
- PRTuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyPatent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T, Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,168 entitled, "Delta Opioid Receptor Antagonists Reprogram Immunosuppresive Microenvironment to Boost Immunotherapy." The patent is directed to, among other things, administration of DOR antagonists to subjects having cancer associa
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECAmendment: TuHURA Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related CancersTAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.The "Study May Proceed" notice from the FDA allows the Company to examine TBS-2025 in a Phase 1b study evaluating the safety and potential efficacy of monotherapy at different doses in patients wit
- PRTuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceTAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY. H.C. Wainwright 28th Annual Global Investment ConferenceDate:Monday, September 14th Time:4:00pm ETFormat:Fireside Chat & 1x1 Meetings To register and view the presentation, please CLICK HERE. An archived webcast of the Fireside Chat will be available on the Events Page in the investor secti
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by TuHURA Biosciences Inc.SCHEDULE 13D/A - TuHURA Biosciences, Inc./NV (0001498382) (Subject)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECSEC Form 10-Q filed by TuHURA Biosciences Inc.10-Q - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateTAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update. "We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. James Bianco, President and CEO of TuHURA Biosciences. "In the second half, we anticipate receiving safe-to-proceed feedback from FDA and to initiating ou
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth ConferenceTAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the Canaccord Genuity's 46th Annual Growth Conference taking place in Boston, MA.Canaccord Genuity 46th Annual Growth ConferenceDate: Wednesday, August 12, 2026Time: 12:30pm ETTo register and view the presentation, please CLICK HERE. An archived webcast of the Canaccord presentation will be available on the Events Page in the Investor Section of T
- SECSEC Form DEFA14A filed by TuHURA Biosciences Inc.DEFA14A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECSEC Form DEF 14A filed by TuHURA Biosciences Inc.DEF 14A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECSEC Form PRE 14A filed by TuHURA Biosciences Inc.PRE 14A - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- SECTuHURA Biosciences Inc. filed SEC Form 8-K: Shareholder Director Nominations8-K - TuHURA Biosciences, Inc./NV (0001498382) (Filer)
- PRTuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related CancersThe IND is aligned with guidance previously provided by the U.S. Food and Drug Administration (FDA) on the development pathway for both monotherapy and combination with menin inhibitors for Acute Myeloid Leukemia (AML)The FDA noted that the requested meeting would not be necessary and that it will instead provide written responses to questions and information related to the Company's proposed Phase 1b/2 development plan for TBS-2025 in AML The Company is targeting initiation of the Phase 1b/2 study in the second half of 2026TAMPA, Fla., June 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeu
HURA FAQ
5 questionsWhere does HURA stock trade?
TuHURA Biosciences Inc. (HURA) is listed on NASDAQ.What sector and industry is HURA in?
TuHURA Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about HURA?
TuHURA Biosciences Inc. has had 4 recent analyst actions on file. The most recent action was from Citizens: Mkt Outperform with a $900.00 price target on 2026-04-27. Recent price targets range from $900.00 to $1500.00.What companies are similar to HURA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare HURA side-by-side with any of them on Quantisnow.How can I track HURA on Quantisnow?
Quantisnow aggregates TuHURA Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HURA to receive live email and push alerts on every new disclosure.